Ranbaxy Invalidates Pfizer's 281 Patent in the Netherlands

Ranbaxy Laboratories Ltd has announced that The District Court of The Hague has handed down a decision in the Company's case against (Pfizer) Warner-Lambert over the cholesterol -lowering drug, atorvastatin, which is marketed by Pfizer as Lipitor(r). The three-judge panel held that (Pfizer) Warner-Lambert's European Patent 409 281 was invalid in the Netherlands. However, the Company's atorvastatin product was ruled to infringe the broadest claims of (Pfizer) Warner-Lambert's European Patent 247 633 in the Netherlands. The Company is evaluating this decision and will decide on its course of action shortly.

Source : Equity Bulls

Keywords